儿童重症百日咳治疗策略研究进展

吴小英; 李丽君; 姚开虎; 许红梅; 符州

doi:10.7499/j.issn.1008-8830.2010105

PDF(1382 KB)

HTML

中国当代儿科杂志 ›› 2021, Vol. 23 ›› Issue (2) : 192-197. DOI: 10.7499/j.issn.1008-8830.2010105

综述

儿童重症百日咳治疗策略研究进展

吴小英¹, 李丽君², 姚开虎³, 许红梅¹, 符州⁴

作者信息 +

Research advances in the treatment strategies for severe pertussis in children

WU Xiao-Ying¹, LI Li-Jun², YAO Kai-Hu³, XU Hong-Mei¹, FU Zhou⁴

Author information +

文章历史 +

摘要

对于重症百日咳，目前临床上主要采用尽早使用敏感抗生素、综合性的对症支持治疗。但部分重症患儿对常用药物及重症监护室常见救治措施的治疗反应不理想，死亡风险大。研究提示如果早期实施某些治疗措施，如换血治疗等可减少死亡，但仍缺乏统一的实施规范。如何确定重症百日咳的治疗方案，提高临床救治能力仍然是一个棘手的问题。现对重症百日咳的治疗进展进行综述，旨在为临床治疗实践和研究提供参考。

Abstract

At present, effective antibiotics and comprehensive symptomatic/supportive treatment as early as possible are mainly used for the treatment of severe pertussis in clinical practice. However, some children with severe pertussis have unsatisfactory response to commonly used drugs and treatment measures in the intensive care unit and thus have a high risk of death. Studies have shown that certain treatment measures given in the early stage, such as exchange transfusion, may help reduce deaths, but there is still a lack of uniform implementation norms. How to determine the treatment regimen for severe pertussis and improve treatment ability remains a difficult issue in clinical practice. This article reviews the advances in the treatment of severe pertussis, in order to provide a reference for clinical treatment and research.

导出引用

吴小英, 李丽君, 姚开虎, 许红梅, 符州. 儿童重症百日咳治疗策略研究进展[J]. 中国当代儿科杂志. 2021, 23(2): 192-197 https://doi.org/10.7499/j.issn.1008-8830.2010105

WU Xiao-Ying, LI Li-Jun, YAO Kai-Hu, XU Hong-Mei, FU Zhou. Research advances in the treatment strategies for severe pertussis in children[J]. Chinese Journal of Contemporary Pediatrics. 2021, 23(2): 192-197 https://doi.org/10.7499/j.issn.1008-8830.2010105

参考文献

[1] Skoff TH, Hadler S, Hariri S. The epidemiology of nationally reported pertussis in the United States, 2000-2016[J]. Clin Infect Dis, 2019, 68(10):1634-1640.
[2] 吴小英, 甘川. 婴幼儿重症百日咳死亡相关因素分析[J]. 临床儿科杂志, 2020, 38(6):432-437.
[3] Gil-Prieto R, Walter S, San-Román-Montero J, et al. Paediatric hospitalizations due to whooping cough in Spain (1997-2017)[J]. Vaccine, 2019, 37(43):6342-6347.
[4] Yeung KHT, Duclos P, Nelson EAS, et al. An update of the global burden of pertussis in children younger than 5 years:a modelling study[J]. Lancet Infect Dis, 2017, 17(9):974-980.
[5] Kavitha TK, Samprathi M, Jayashree M, et al. Clinical profile of critical pertussis in children at a pediatric intensive care unit in Northern India[J]. Indian Pediatr, 2020, 57(3):228-231.
[6] Kazantzi MS, Prezerakou A, Kalamitsou SN, et al. Characteristics of Bordetella pertussis infection among infants and children admitted to paediatric intensive care units in Greece:a multicentre, 11-year study[J]. J Paediatr Child Health, 2017, 53(3):257-262.
[7] 姚开虎, 李丽君. 重症百日咳的诊断及其死亡风险因素研究进展[J]. 中华实用儿科临床杂志, 2019, 34(22):1681-1685.
[8] 中华医学会儿科学分会感染学组,《中华儿科杂志》编辑委员会. 中国儿童百日咳诊断及治疗建议[J]. 中华儿科杂志, 2017, 55(8):568-572.
[9] Li LJ, Deng JK, Ma X, et al. High prevalence of macrolide-resistant Bordetella pertussis and ptxP1 genotype, mainland China, 2014-2016[J]. Emerg Infect Dis, 2019, 25(12):2205-2214.
[10] 李丽君, 刘莹, 贾举, 等. 新生儿百日咳致病株抗菌药物敏感性和抗原基因型研究[J]. 中国当代儿科杂志, 2019, 21(3):208-213.
[11] Hua CZ, Wang HJ, Zhang Z, et al. In vitro activity and clinical efficacy of macrolides, cefoperazone-sulbactam and piperacillin/piperacillin-tazobactam against Bordetella pertussis and the clinical manifestations in pertussis patients due to these isolates:a single-centre study in Zhejiang Province, China[J]. J Glob Antimicrob Resist, 2019, 18:47-51.
[12] Evered J, Pfeifer E, Gracianette M. Caffeine to prevent respiratory failure and improve outcome in infant pertussis[J]. BMJ Case Rep, 2018, 2018:bcr2017223102.
[13] Straney L, Schibler A, Ganeshalingham A, et al. Burden and outcomes of severe pertussis infection in critically ill infants[J]. Pediatr Crit Care Med, 2016, 17(8):735-742.
[14] Gillis J, Grattan-Smith T, Kilham H. Artificial ventilation in severe pertussis[J]. Arch Dis Child, 1988, 63(4):364-367.
[15] Berger JT, Carcillo JA, Shanley TP, et al. Critical pertussis illness in children:a multicenter prospective cohort study[J]. Pediatr Crit Care Med, 2013, 14(4):356-365.
[16] Winter K, Zipprich J, Harriman K, et al. Risk factors associated with infant deaths from pertussis:a case-control study[J]. Clin Infect Dis, 2015, 61(7):1099-1106.
[17] Palvo F, Fabro AT, Cervi MC, et al. Severe pertussis infection:a clinicopathological study[J]. Medicine (Baltimore), 2017, 96(48):e8823.
[18] Rowlands HE, Goldman AP, Harrington K, et al. Impact of rapid leukodepletion on the outcome of severe clinical pertussis in young infants[J]. Pediatrics, 2010, 126(4):e816-e827.
[19] Kuperman A, Hoffmann Y, Glikman D, et al. Severe pertussis and hyperleukocytosis:is it time to change for exchange?[J]. Transfusion, 2014, 54(6):1630-1633.
[20] 李敏霞, 王乔宇, 曲东, 等. 白细胞单采术治疗小儿重症百日咳合并高白细胞血症一例并文献复习[J]. 中国小儿急救医学, 2020, 27(4):312-314.
[21] Oñoro G, Salido AG, Martínez IM, et al. Leukoreduction in patients with severe pertussis with hyperleukocytosis[J]. Pediatr Infect Dis J, 2012, 31(8):873-876.
[22] Scanlon K, Skerry C, Carbonetti N. Association of pertussis toxin with severe pertussis disease[J]. Toxins (Basel), 2019, 11(7):373.
[23] Nieves D, Bradley JS, Gargas J, et al. Exchange blood transfusion in the management of severe pertussis in young infants[J]. Pediatr Infect Dis J, 2013, 32(6):698-699.
[24] Tian SF, Wang HM, Deng JK. Fatal malignant pertussis with hyperleukocytosis in a Chinese infant:a case report and literature review[J]. Medicine (Baltimore), 2018, 97(17):e0549.
[25] Cherry JD, Wendorf K, Bregman B, et al. An observational study of severe pertussis in 100 infants ≤ 120 days of age[J]. Pediatr Infect Dis J, 2018, 37(3):202-205.
[26] Paddock CD, Sanden GN, Cherry JD, et al. Pathology and pathogenesis of fatal Bordetella pertussis infection in infants[J]. Clin Infect Dis, 2008, 47(3):328-338.
[27] Hansmann G, Koestenberger M, Alastalo TP, et al. 2019 updated consensus statement on the diagnosis and treatment of pediatric pulmonary hypertension:the European Pediatric Pulmonary Vascular Disease Network (EPPVDN), endorsed by AEPC, ESPR and ISHLT[J]. J Heart Lung Transplant, 2019, 38(9):879-901.
[28] Skladal D, Horak E, Frühwirth M, et al. Successful treatment of ARDS and severe pulmonary hypertension in a child with Bordetella pertussis infection[J]. Wien Klin Wochenschr, 2004, 116(21/22):760-762.
[29] Abman SH, Hansmann G, Archer SL, et al. Pediatric pulmonary hypertension:guidelines from the American Heart Association and American Thoracic Society[J]. Circulation, 2015, 132(21):2037-2099.
[30] Flak TA, Goldman WE. Autotoxicity of nitric oxide in airway disease[J]. Am J Respir Crit Care Med, 1996, 154(4 Pt 2):S202-S206.
[31] Halasa NB, Barr FE, Johnson JE, et al. Fatal pulmonary hypertension associated with pertussis in infants:does extracorporeal membrane oxygenation have a role?[J]. Pediatrics, 2003, 112(6 Pt 1):1274-1278.
[32] Barbaro RP, Boonstra PS, Paden ML, et al. Development and validation of the pediatric risk estimate score for children using extracorporeal respiratory support (Ped-RESCUERS)[J]. Intensive Care Med, 2016, 42(5):879-888.
[33] Domico M, Ridout D, Maclaren G, et al. Extracorporeal membrane oxygenation for pertussis:predictors of outcome including pulmonary hypertension and leukodepletion[J]. Pediatr Crit Care Med, 2018, 19(3):254-261.
[34] Assy J, Séguéla PE, Guillet E, et al. Severe neonatal pertussis treated by leukodepletion and early extra corporeal membrane oxygenation[J]. Pediatr Infect Dis J, 2015, 34(9):1029-1030.
[35] Krawiec C, Ballinger K, Halstead ES. Intrapulmonary percussive ventilation as an airway clearance technique during venoarterial extracorporeal life support in an infant with pertussis[J]. Front Pediatr, 2017, 5:99.
[36] Shi JY, Wang CX, Cui Y, et al. Extracorporeal membrane oxygenation with prone position ventilation successfully rescues infantile pertussis:a case report and literature review[J]. BMC Pediatr, 2018, 18(1):377.
[37] 方峰, 俞蕙. 小儿传染病学[M]. 5版. 北京:人民卫生出版社, 2020:160-165.
[38] Granström M, Olinder-Nielsen AM, Holmblad P, et al. Specific immunoglobulin for treatment of whooping cough[J]. Lancet, 1991, 338(8777):1230-1233.
[39] Halperin SA, Vaudry W, Boucher FD, et al. Is pertussis immune globulin efficacious for the treatment of hospitalized infants with pertussis? No answer yet[J]. Pediatr Infect Dis J, 2007, 26(1):79-81.